UK Competition Body Backs Up Claim That Pfizer & Flynn Abused Dominant Position With ‘Excessive’ Prices

The UK CMA has explained why it believes Pfizer and Flynn Pharma abused a dominant market position by charging “excessive and unfair” prices for a generic epilepsy drug, while the two companies have laid out their the grounds for appealing against the decision.

Symbol of law and justice
The CMA has outlined why it thinks Pfizer and Flynn abused a dominant position

The UK Competition and Markets Authority has revealed the reasoning behind its decision to fine Pfizer and Flynn Pharma for abuse of a dominant market position by charging “excessive and unfair” prices for the generic anti-epilepsy drug, phenytoin sodium capsules.

The CMA says the companies faced only “weak” competitive constraints in the form of other formulations of phenytoin sodium or...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access